| GBP deficiency . | Disease or immune challenge . | Phenotype . | Reference . |
|---|---|---|---|
| GBP KO mice | |||
| Gbp1−/− | L. monocytogenes | Susceptible to orogastric infection | Kim et al. (2011) |
| M. bovis BCG | Susceptible to i.v. infection | Kim et al. (2011) | |
| T. gondii | Susceptible to s.c. infection | Selleck et al. (2013) | |
| Gbp2−/− | T. gondii | Susceptible to i.p. infection | Degrandi et al. (2013) |
| L. monocytogenes | Resistant to i.p. infection | Degrandi et al. (2013) | |
| F. novicida | Susceptible to s.c. infection and reduced serum IL-18 | Meunier et al. (2015) | |
| OMV i.p. challenge | Resistant to endotoxemia after poly I:C priming; reduced serum IL-1β plus IL-18 | Finethy et al. (2017); Santos et al. (2018) | |
| Gbp5−/− | L. monocytogenes | Susceptible to orogastric infection and insensitive to the caspase-1 inhibitor z-YVAD-FMK | Shenoy et al. (2012) |
| LPS i.p. challenge | Reduced serum IL-1β plus IL-18 and reduced active caspase-1 in splenic macrophages | Shenoy et al. (2012) | |
| MDP i.p. challenge | Impaired peritonitis and reduced active caspase-1 in peritoneal neutrophils | Shenoy et al. (2012) | |
| Alum i.p. challenge | Normal peritonitis | Shenoy et al. (2012) | |
| MSU i.p. challenge | Normal peritonitis | Shenoy et al. (2012) | |
| Gbpchr3−/− | T. gondii | Susceptible to i.p. infection | Yamamoto et al. (2012) |
| L. monocytogenes | Resistant to i.p. infection | Yamamoto et al. (2012) | |
| F. novicida | Susceptible to s.c. infection and reduced serum IL-18 | Meunier et al. (2015); Man et al. (2016); Wallet et al. (2017) | |
| L. pneumophila | Susceptible to cytosolic ΔsdhA Lpn administered oropharangeally | Liu et al. (2018) | |
| Norovirus | Susceptible to peroral infection in combination with Ifnar1 deficiency | Biering et al. (2017) | |
| OMV i.p. challenge | Resistant to endotoxemia after poly I:C priming; reduced serum IL-1β plus IL-18 | Finethy et al. (2017); Santos et al. (2018) | |
| LPS i.p. challenge | Resistant to endotoxemia after poly I:C priming; reduced serum IL-1β plus IL-18 | Santos et al. (2018) | |
| Human GBP SNPs/alterations | |||
| GBP2 | Hepatitis B virus | IFN treatment responsiveness vs. nonresponsiveness | King et al. (2002) |
| (41544 A/G)a | |||
| (41556 G/C)a | |||
| GBP3 (rs7911) | Fibromyalgia | Protective role in pathophysiology of FM | Parisien et al. (2017) |
| GBP5 (spliced GBP5ta-97 AA truncation) | Cutaneous T cell lymphoma | High isoform expression in tumor tissues and cell lines | Fellenberg et al. (2004) |
| GBP7 (rs1803632) | Malaria | Promoter mutations associated with higher disease incidence | Apinjoh et al. (2014) |
| GBP deficiency . | Disease or immune challenge . | Phenotype . | Reference . |
|---|---|---|---|
| GBP KO mice | |||
| Gbp1−/− | L. monocytogenes | Susceptible to orogastric infection | Kim et al. (2011) |
| M. bovis BCG | Susceptible to i.v. infection | Kim et al. (2011) | |
| T. gondii | Susceptible to s.c. infection | Selleck et al. (2013) | |
| Gbp2−/− | T. gondii | Susceptible to i.p. infection | Degrandi et al. (2013) |
| L. monocytogenes | Resistant to i.p. infection | Degrandi et al. (2013) | |
| F. novicida | Susceptible to s.c. infection and reduced serum IL-18 | Meunier et al. (2015) | |
| OMV i.p. challenge | Resistant to endotoxemia after poly I:C priming; reduced serum IL-1β plus IL-18 | Finethy et al. (2017); Santos et al. (2018) | |
| Gbp5−/− | L. monocytogenes | Susceptible to orogastric infection and insensitive to the caspase-1 inhibitor z-YVAD-FMK | Shenoy et al. (2012) |
| LPS i.p. challenge | Reduced serum IL-1β plus IL-18 and reduced active caspase-1 in splenic macrophages | Shenoy et al. (2012) | |
| MDP i.p. challenge | Impaired peritonitis and reduced active caspase-1 in peritoneal neutrophils | Shenoy et al. (2012) | |
| Alum i.p. challenge | Normal peritonitis | Shenoy et al. (2012) | |
| MSU i.p. challenge | Normal peritonitis | Shenoy et al. (2012) | |
| Gbpchr3−/− | T. gondii | Susceptible to i.p. infection | Yamamoto et al. (2012) |
| L. monocytogenes | Resistant to i.p. infection | Yamamoto et al. (2012) | |
| F. novicida | Susceptible to s.c. infection and reduced serum IL-18 | Meunier et al. (2015); Man et al. (2016); Wallet et al. (2017) | |
| L. pneumophila | Susceptible to cytosolic ΔsdhA Lpn administered oropharangeally | Liu et al. (2018) | |
| Norovirus | Susceptible to peroral infection in combination with Ifnar1 deficiency | Biering et al. (2017) | |
| OMV i.p. challenge | Resistant to endotoxemia after poly I:C priming; reduced serum IL-1β plus IL-18 | Finethy et al. (2017); Santos et al. (2018) | |
| LPS i.p. challenge | Resistant to endotoxemia after poly I:C priming; reduced serum IL-1β plus IL-18 | Santos et al. (2018) | |
| Human GBP SNPs/alterations | |||
| GBP2 | Hepatitis B virus | IFN treatment responsiveness vs. nonresponsiveness | King et al. (2002) |
| (41544 A/G)a | |||
| (41556 G/C)a | |||
| GBP3 (rs7911) | Fibromyalgia | Protective role in pathophysiology of FM | Parisien et al. (2017) |
| GBP5 (spliced GBP5ta-97 AA truncation) | Cutaneous T cell lymphoma | High isoform expression in tumor tissues and cell lines | Fellenberg et al. (2004) |
| GBP7 (rs1803632) | Malaria | Promoter mutations associated with higher disease incidence | Apinjoh et al. (2014) |
rs, dbSNP database number; MDP, muramyl dipeptide; MSU, monosodium ureate; FM, fibromyalgia.
JSNP, Japanese Single Nucleotide Polymorphisms database.